fda approved glp-1 gip medications 2025 Pipeline Update: November - Prime Therapeutics GLP Weight Loss Medications |

doi: 10.1016/S0140-6736(19)31149-3 83 HusainMBirkenfeldALDonsmarkMDunganKEliaschewitzFGFrancoDRet al

An estimated $200-$230 billion in annual branded revenue will lose exclusivity protection between 2025 and 2030, with drugs like Keytruda ($29B+ in 2024 sales), Eliquis ($13B+ for BMS alone), and Opdivo concentrated in a narrow 2026-2028 window

A clinical pathway your biology has been waiting for

Set roommate rules

19-20 These two models would assess rebates for certain drugs payable under Medicare Part D and Part B, respectively, if prices exceed those paid in comparable countries for the same drugs

Your medication already provides sustained GLP-1 receptor activation at levels no supplement can match